# US 2003/0069306 A1 · Carbamate compounds for use in preventing or treating neuropathic pain and cluster and migraine headache-associated pain

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2003/0069306 A1
- Document ID: US20030069306A1
- Status: Published application
- Kind: A1
- Application number: 10/192,973
- Filed: 2002-07-11
- Published: 2003-04-10
- Earliest claimed: 2001-07-16
- Inventors: Ellen C. Codd; Carlos R. Plata-Salaman; Boyu Zhao
- Web page: https://patentgrep.com/patent/US20030069306A1

## CPC

- A61K 31/325: Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof (thiurams A61K31/145)
- A61K 31/27: of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
- A61P 25/02: for peripheral neuropathies
- A61P 25/04: Centrally acting analgesics, e.g. opioids
- A61P 25/06: Antimigraine agents
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

This invention is directed to a method for preventing or treating neuropathic pain and cluster and migraine headache-associated pain comprising administering to a subject in need thereof a therapeutically effective amount of an enantiomer of Formula (I) substantially free of other enantiomers or an enantiomeric mixture wherein an enantiomer of Formula (I) predominates: 1 wherein phenyl is substituted at X with one to five halogen atoms independently selected from the group consisting of fluorine, chlorine, bromine and iodine; and; R1 and R2 are independently selected from the group consisting of hydrogen and C1-C4 alkyl; wherein C1-C4 alkyl is optionally substituted with phenyl (wherein phenyl is optionally substituted with substituents independently selected from the group consisting of hydrogen, halogen, C1-C4 alkyl, C1-C4 alkoxy, amino, nitro and cyano).

## Claims

### Claim 1

A method for preventing or treating neuropathic pain and cluster and migraine headache-associated pain comprising administering to a subject in need thereof a therapeutically effective amount of an enantiomer of Formula (I) substantially free of other enantiomers or an enantiomeric mixture wherein an enantiomer of Formula (I) predominates:
11
wherein
phenyl is substituted at X with one to five halogen atoms independently selected from the group consisting of fluorine, chlorine, bromine and iodine; and,
R1 and R2 are independently selected from the group consisting of hydrogen and C1-C4 alkyl; wherein C1-C4 alkyl is optionally substituted with phenyl (wherein phenyl is optionally substituted with substituents independently selected from the group consisting of halogen, C1-C4 alkyl, C1-C4 alkoxy, amino, nitro and cyano).

### Claim 2

A method for preventing or treating neuropathic pain comprising administering to a subject in need thereof a therapeutically effective amount of an enantiomer of Formula (I) substantially free of other enantiomers or an enantiomeric mixture wherein an enantiomer of Formula (I) predominates:
12
wherein
phenyl is substituted at X with one to five halogen atoms independently selected from the group consisting of fluorine, chlorine, bromine and iodine; and,
R1 and R2 are independently selected from the group consisting of hydrogen and C1-C4 alkyl; wherein C1-C4 alkyl is optionally substituted with phenyl (wherein phenyl is optionally substituted with substituents independently selected from the group consisting of halogen, C1-C4 alkyl, C1-C4 alkoxy, amino, nitro and cyano).

### Claim 3

A method for preventing or treating cluster and migraine headache-associated pain comprising administering to a subject in need thereof a therapeutically effective amount of an enantiomer of Formula (I) substantially free of other enantiomers or an enantiomeric mixture wherein an enantiomer of Formula (I) predominates:
13
wherein
phenyl is substituted at X with one to five halogen atoms independently selected from the group consisting of fluorine, chlorine, bromine and iodine; and,
R1 and R2 are independently selected from the group consisting of hydrogen and C1-C4 alkyl; wherein C1-C4 alkyl is optionally substituted with phenyl (wherein phenyl is optionally substituted with substituents independently selected from the group consisting of halogen, C1-C4 alkyl, C1-C4 alkoxy, amino, nitro and cyano).

### Claim 4 (depends on 1)

The method of claim 1 wherein X is chlorine.

### Claim 5 (depends on 1)

The method of claim 1 wherein X is substituted at the ortho position of the phenyl ring.

### Claim 6 (depends on 1)

The method of claim 1 wherein R1 and R2 are selected from hydrogen.

### Claim 7 (depends on 1)

The method of claim 1 wherein an enantiomer of Formula (I) predominates to the extent of about 90% or greater.

### Claim 8 (depends on 1)

The method of claim 1 wherein an enantiomer of Formula (I) predominates to the extent of about 98% or greater.

### Claim 9 (depends on 1)

The method of claim 1 wherein the enantiomer of Formula (I) substantially free of other enantiomers is an enantiomer of Formula (Ia) substantially free of other enantiomers or an enantiomeric mixture wherein an enantiomer of Formula (Ia) predominates:
14
wherein
R1 and R2 are independently selected from the group consisting of hydrogen and C1-C4 alkyl; wherein C1-C4 alkyl is optionally substituted with phenyl (wherein phenyl is optionally substituted with substituents independently selected from the group consisting of halogen, C1-C4 alkyl, C1-C4 alkoxy, amino, nitro and cyano).

### Claim 10 (depends on 9)

The method of claim 9 wherein R1 and R2 are selected from hydrogen.

### Claim 11 (depends on 9)

The method of claim 9 wherein an enantiomer of Formula (Ia) predominates to the extent of about 90% or greater.

### Claim 12 (depends on 9)

The method of claim 9 wherein an enantiomer of Formula (Ia) predominates to the extent of about 98% or greater.

### Claim 13 (depends on 1)

The method of claim 1 wherein the enantiomer of Formula (I) substantially free of other enantiomers is an enantiomer of Formula (Ib) substantially free of other enantiomers or an enantiomeric mixture wherein the enantiomer of Formula (Ib) predominates:
15

### Claim 14 (depends on 13)

The method of claim 13 wherein the enantiomer of Formula (Ib) predominates to the extent of about 90% or greater.

### Claim 15 (depends on 13)

The method of claim 13 wherein the enantiomer of Formula (Ib) predominates to the extent of about 98% or greater.

### Claim 16 (depends on 2)

The method of claim 2 wherein the enantiomer of Formula (I) substantially free of other enantiomers is an enantiomer of Formula (Ib) substantially free of other enantiomers or an enantiomeric mixture wherein the enantiomer of Formula (Ib) predominates:
16

### Claim 17 (depends on 16)

The method of claim 16 wherein the enantiomer of Formula (Ib) predominates to the extent of about 90% or greater.

### Claim 18 (depends on 16)

The method of claim 16 wherein the enantiomer of Formula (Ib) predominates to the extent of about 98% or greater.

### Claim 19 (depends on 2)

The method of claim 2 wherein neuropathic pain results from chronic or debilitating conditions.

### Claim 20 (depends on 19)

The method of claim 19 wherein the chronic or debilitating conditions are selected from the group consisting of painful diabetic peripheral neuropathy, post-herpetic neuralgia, trigeminal neuralgia, post-stroke pain, multiple sclerosis-associated pain, neuropathies-associated pain such as in idiopathic or post-traumatic neuropathy and mononeuritis, HIV-associated neuropathic pain, cancer-associated neuropathic pain, carpal tunnel-associated neuropathic pain, spinal cord injury-associated pain, complex regional pain syndrome, fibromyalgia-associated neuropathic pain, lumbar and cervical pain, reflex sympathic dystrophy, phantom limb syndrome and other chronic and debilitating condition-associated pain syndromes.

### Claim 21 (depends on 16)

The method of claim 16 wherein the therapeutically effective amount is from about 0.01 mg/Kg/dose to about 100 mg/Kg/dose.

### Claim 22 (depends on 3)

The method of claim 3 wherein the enantiomer of Formula (I) substantially free of other enantiomers is an enantiomer of Formula (Ib) substantially free of other enantiomers or an enantiomeric mixture wherein the enantiomer of Formula (Ib) predominates:
17

### Claim 23 (depends on 22)

The method of claim 22 wherein the enantiomer of Formula (Ib) predominates to the extent of about 90% or greater.

### Claim 24 (depends on 22)

The method of claim 22 wherein the enantiomer of Formula (Ib) predominates to the extent of about 98% or greater.

### Claim 25 (depends on 1)

The method of claim 1 wherein the method is a method for slowing or delaying the progression of neuropathic pain and cluster and migraine headache-associated pain comprising administering to a subject in need thereof a therapeutically effective amount of an enantiomer of Formula (I) substantially free of other enantiomers or an enantiomeric mixture wherein an enantiomer of Formula (I) predominates.

### Claim 26 (depends on 25)

The method of claim 25 wherein the therapeutically effective amount is from about 0.01 mg/Kg/dose to about 100 mg/Kg/dose.
